COMP <GO>
TMCI vs INFU // EV/EBITDA & P/E VALUATION
Treace Medical Concepts Inc. (NASDAQ) VS. InfuSystems Holdings Inc. (NYSE) • 15-METRIC TALLY: TMCI 2
— INFU 8
■ METRIC PARITY
LAST: $5.06 (+4.76%) • MKT CAP: $329.1M
valuation
—
LAST: $14.45 (+0.91%) • MKT CAP: $287.8M
valuation
24.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMCI VS. INFU)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TMCI | INFU | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.80% | 56.00% | +23.80 | TMCI | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.40% | 12.80% | -45.20 | INFU | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 24.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.96% | 8.29% | -17.25 | INFU | /fcf-yield <GO> |
| Operating Margin | -25.50% | 8.30% | -33.80 | INFU | /operating-margins <GO> |
| Net Profit Margin | -27.70% | 4.60% | -32.30 | INFU | /net-margins <GO> |
| Revenue Growth (YoY) | 1.60% | 6.40% | -4.80 | INFU | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.90 | 5.16 | -4.26 | INFU | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | INFU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.6 | 58.6 | -6.97 | INFU | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 40.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $329.1M | $287.8M | $41.3M | TMCI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TMCI REV | INFU REV | TMCI GROSS % | INFU GROSS % | TMCI FCF | INFU FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $212.7M | $143.4M | 79.8% | 56.0% | -$29.5M | $23.8M |
| FY 2024 | $209.4M | $134.9M | 80.4% | 52.2% | -$48.8M | $19.4M |
| FY 2023 | $187.1M | $125.8M | — | — | -$34.6M | $11.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMCI // BETA —
INFU // BETA —